DNA Script and leading healthcare solutions provider awarded up to $26M by ARPA-H to advance cell-free DNA bioproduction. | August 4, 2026. FLASH program, in collaboration with GE HealthCare, to support development of faster, distributed DNA manufacturing for next-generation therapies Paris, France, 04 August 2026: DNA Script, a pioneer in DNA synthesis providing scientists with rapid, on-demand access to high-quality DNA, today announced that in collaboration with prime awardee GE HealthCare, they have been awarded up to $26 million in funding for a four-year initiative from the Advanced Research Projects Agency for Health (ARPA-H). The award will support the advancement of the Flexible Automation for Scalable Health (FLASH) program, focused on the development of scalable cell-free DNA bioproduction capabilities and powered in part by DNA Script's enzymatic DNA synthesis (EDS) technology and SYNTAX(R) platform. Led by GE HealthCare, the FLASH program aims to develop a modular, automated platform for the rapid, distributed manufacturing of high-fidelity DNA to support research and potential future applications in personalized medicines, vaccines, and other genetic health technologies. DNA Script's EDS technology supports this goal by enabling faster and more flexible DNA manufacturing workflows. DNA Script is contributing its EDS technology and acting as the technical solution integrator for the project. The Company has adapted its solution to incorporate GE HealthCare's proprietary DNA scaling technology, complementing DNA Script's EDS technology, with the goal of eventually deploying the integrated platform across U.S. medical research centers, universities, and federal agencies. John Schiel, Program Manager, ARPA-H, said: "ARPA-H solutions are designed to address hard problems with bold, practical approaches. Projects like FLASH exemplify how scalable, platform-based technologies can transform the way health solutions are developed, produced, and delivered." Marc Montserrat, Chief Executive Officer, DNA Script, commented: "Our enzymatic DNA synthesis platform is ideally suited for the on-demand manufacturing model FLASH is pioneering. Collaborating with GE HealthCare on an ARPA-H program of this scale shortens the path from research bench to patient bedside for next-generation therapies, personalized vaccines, and the broader genetic-medicine pipeline." John Nelson, Senior Biosciences Principal and FLASH program lead, GE HealthCare's Healthcare Technology and Innovation Center, added: "GE HealthCare's Technology & Innovation Center drives exploratory and translational research focused on addressing healthcare challenges through federal funding, academic collaboration, and private-sector research and development. As personalized and time-sensitive genetic medicines continue to advance, there is a growing need for manufacturing approaches that are faster, more flexible, and more accessible. Our vision for the FLASH program is to develop new DNA-based medicines on demand quickly, safely, and at scale." The FLASH program brings together expertise in automation, DNA synthesis and scaling, purification, and genomic validation. For more information on the award and research, visit: https://arpa-h.gov/explore-funding/awards/3926 Media contact About DNA Script dnascript.com DNA Script is the programmable biology company, developing next-generation enzymatic DNA synthesis (EDS) technologies that enable faster, more flexible, and scalable access to DNA. The Company's proprietary platforms support both decentralized, on-demand DNA production in research environments and biomanufacturing of GMP-grade DNA templates for advanced therapeutic applications. By replacing traditional DNA supply constraints with programmable workflows, DNA Script helps organizations across the therapeutic ecosystem accelerate development, expand access, and improve patient outcomes. For DNA Script on LinkedIn (@DNA Script)

DNA Script expands access to on-demand DNA synthesis in India through distributor agreement with Imperial Life Sciences. PARIS, FRANCE | july 14, 2026. Brings decentralized, in-house DNA synthesis capabilities to researchers in a rapidly growing biotechnology market. Paris, France, 30 June 2026: DNA Script, the programmable biology company developing next-generation enzymatic DNA synthesis (EDS) technologies, today announced a new distribution agreement with Imperial Life Sciences (ILS), expanding access to the Company's SYNTAX(R) platform across India. Under the agreement, ILS will distribute DNA Script's SYNTAX platform throughout the country, providing local sales, technical support and application expertise to researchers seeking faster, more flexible access to high-quality single-stranded DNA (ssDNA) oligonucleotides. The agreement with ILS builds on DNA Script's recent expansion of its global distribution network across Latin America and East Asia1, extending the availability of the SYNTAX platform into another key growth market for life sciences research. The partnership supports the Company's strategy to broaden adoption of decentralized, on-demand DNA synthesis and strengthen access to DNA production capabilities in rapidly growing research ecosystems. India is one of the world's fastest-growing biotechnology markets, creating increasing demand for technologies that accelerate research and reduce reliance on overseas supply chains. With over three decades of experience supporting India's research community, ILS brings an established nationwide network spanning academic institutions, biotechnology companies, pharmaceutical organizations and research laboratories. Oligonucleotides are essential components of life sciences research but despite this, many researchers continue to rely on external suppliers, resulting in delays that can slow scientific progress and extend development timelines. DNA Script's automated benchtop SYNTAX platform addresses these challenges by enabling researchers to synthesize ssDNA oligonucleotides directly within their laboratories in just a few hours. By shifting DNA production from centralized manufacturing facilities to the laboratory bench, researchers gain greater control over workflows, faster turnaround times and reduced dependence on complex supply chains. The SYNTAX platform combines DNA synthesis, purification and normalization in a single automated workflow, allowing laboratories to produce up to 384 oligonucleotides in parallel and accelerate design-build-test cycles across a wide range of research applications. Marc Montserrat, Chief Executive Officer, DNA Script, commented: "India's life sciences sector is moving fast, and researchers need the tools to match that pace. Partnering with Imperial Life Sciences means laboratories across India can now access SYNTAX locally, with the speed, quality and scalability their research demands. Together, we are helping researchers reduce reliance on external DNA supply chains and accelerate scientific discovery through on-demand, in-house DNA synthesis." Neeraj Gupta, Director (sales), Imperial Life Sciences, said: "We are excited to partner with DNA Script to bring the SYNTAX platform to researchers across India. This innovative technology empowers scientists to accelerate research by reducing dependency on external oligo supplies and significantly shortening the design-build-test cycle. By combining DNA Script's enzymatic DNA synthesis technology with our nationwide reach and technical expertise, we look forward to supporting India's growing genomics, synthetic biology and biotechnology communities with faster and more flexible access to DNA." About DNA Script DNA Script is the programmable biology company, developing next-generation enzymatic DNA synthesis (EDS) technologies that enable faster, more flexible, and scalable access to DNA. The Company's proprietary platforms support both decentralized, on-demand DNA production in research environments and biomanufacturing of GMP-grade DNA templates for advanced therapeutic applications. By replacing traditional DNA supply constraints with programmable workflows, DNA Script helps organizations across the therapeutic ecosystem accelerate development, expand access, and improve patient outcomes. For DNA Script on LinkedIn (@DNA Script). If you want to contact your local distributor visit its distributor page. If you want to learn more about SYNTAX capabilities, visit its product page.

DNA Script expands global access to on-demand DNA synthesis with distributor agreements in Latin America and east asia. * Enables researchers worldwide to access high-quality ssDNA oligonucleotides within hours * Establishes direct distribution networks across Latin America, Japan and South Korea Paris, France, 17 March 2026: DNA Script, a pioneer in DNA synthesis providing scientists with rapid, on-demand access to high-quality DNA, today announced it has signed distribution agreements with Gencell, Bio-Medical Science Co. (BMS), and BioStream Co., expanding global access to the Company's SYNTAX(R) platform for decentralized, in-house and on-demand oligonucleotide production. Under the agreements, Gencell will distribute SYNTAX across Latin America, Bio-Medical Science will cover South Korea, and BioStream will support customers in Japan. This expansion supports DNA Script's strategy to broaden global adoption of SYNTAX and enable researchers located far from major oligonucleotide production hubs in Europe and the United States to access DNA more quickly and reliably. Each distributor is an established life and health sciences company with strong regional networks, enabling local access to DNA synthesis capabilities without reliance on overseas manufacturing. Oligonucleotides are a critical input for a wide range of applications, but researchers located far from large-scale synthesis centers face project delays due to long delivery times or logistical constraints. DNA Script's automated, benchtop SYNTAX platform addresses these challenges by enabling researchers to synthesize ssDNA oligonucleotides directly within the lab in only few hours, shifting the model from centralized supply chains to local DNA production and ensuring geography does not determine scientific speed. Marc Montserrat, Chief Executive Officer, DNA Script, commented: "We're excited to enter these new partnerships as part of our strategy to scale global accessibility and availability of ssDNA oligos, making them available to researchers anywhere in the world. These distributor agreements expand global access to the platform, support the Company's continued growth, and enable researchers to access oligonucleotides more quickly and reliably, regardless of location." Fabio Andrés Zapata, Chief Executive Officer of Gencell, said: "This alliance represents a fundamental step toward accelerating innovation in Latin America. By bringing technologies like SYNTAX closer to researchers in the region, we help reduce development times and drive local biomanufacturing. We are proud to strengthen the region's scientific and technological capabilities, positioning Latin America as an increasingly competitive player in global science and biotechnology." Dukhyun Lim, Vice President of Bio-Medical Science Co., BMS, commented: "SYNTAX offers researchers greater control and speed in oligonucleotide production, enabling increased independence and control over project workflows, and we are pleased to support its availability in South Korea." Iwabuchi Takeshi, President of BioStream Co., added: "This partnership strengthens our ability to deliver advanced life sciences technologies throughout Japan, helping customers reduce dependence on overseas synthesis and long delivery timelines."